Literature DB >> 8409715

Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis.

B S Gendeh1, H Said, A G Gibb, N S Aziz, N Kong, Z M Zahir.   

Abstract

A prospective study was undertaken of 10 chronic renal failure patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) complicated by repeated bouts of peritonitis treated with gentamicin. Each 10-day treatment course consisted of a 120 mg loading dose, followed by 16 mg in 21 of peritoneal dialysate, given four times a day. Serum gentamicin analysed by enzyme immunoassay showed a mean level of 5.2 micrograms/ml, (range 3.7 to 6.6 mg/ml) four hours after the loading dose. Similar levels, well within the therapeutic range, were maintained on the 3rd, 5th, 7th and 9th days of intraperitoneal gentamicin therapy, suggesting no accumulation of gentamicin in the serum. Pure tone audiometry, electronystagmography and clinical assessment were performed during each course of treatment. Although no evidence of ototoxicity was found during the first two courses of gentamicin, but disequilibrium and bobbing oscillopsia were present during the third and fourth courses of gentamicin. These findings could be explained by cumulative injury to the vestibular apparatus caused by repeated therapeutic insults.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8409715     DOI: 10.1017/s0022215100124132

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis.

Authors:  Wen Tang; Yeoungjee Cho; Carmel M Hawley; Sunil V Badve; David W Johnson
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

Review 2.  Experimental, clinical and preventive aspects of ototoxicity.

Authors:  A A Chiodo; P W Alberti
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

Review 3.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.